Comparison of bivalirudin versus heparin(s) during percutaneous coronary interventions in patients receiving prasugrel: A propensity-matched study

Clinical Cardiology

Volumn 37, Issue 1, 2014, Pages 14-20

  Hamon, Martial ^a   Bonello, Laurent ^b,c   Marso, Steven ^d,e   Rao, Sunil V ^f   Valgimigli, Marco ^g   Verheugt, Freek ^h   Gershlick, Anthony ⁱ   Wang, Yamei ^j   Prats, Jayne ^j   Steg, Gabriel P ^a   Deliargyris, Efthymios ^j  

^a INSERM   (France)

^b CAEN UNIVERSITY HOSPITAL   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^d SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^e UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^f DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^g UNIVERSITY OF FERRARA   (Italy)

^h RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ UNIVERSITY OF LEICESTER   (United Kingdom)

^j MEDICINES COMPANY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; HIRULOG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRASUGREL;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLOOD TRANSFUSION; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DEATH; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HOSPITAL COST; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT; OUTPATIENT CARE; PERCUTANEOUS CORONARY INTERVENTION; PROPENSITY SCORE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STABLE ANGINA PECTORIS; UNSTABLE ANGINA PECTORIS; YOUNG ADULT;

AGED; ANTICOAGULANTS; BLOOD TRANSFUSION; CHI-SQUARE DISTRIBUTION; DRUG THERAPY, COMBINATION; FEMALE; HEMORRHAGE; HEPARIN; HIRUDINS; HOSPITAL MORTALITY; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; ODDS RATIO; PEPTIDE FRAGMENTS; PERCUTANEOUS CORONARY INTERVENTION; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PROPENSITY SCORE; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RISK FACTORS; THIOPHENES; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84892562774     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22208     Document Type: Article

References (23)

1. PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation. 2007; 116: 2923-2932.
2. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 357: 2001-2015.
3. TRITON-TIMI 38 Investigators. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet. 2008; 371: 1353-1363.
4. Stone GW, Witzenbichler B, Guagliumi G, et al. HORIZONS-AMI Trial Investigators. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008; 358: 2218-2213.
5. HORIZONS-AMI Trial Investigators. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet. 2011; 377: 2193-2204.
6. Mehran R, Lansky AJ, Witzenbichler B, et al. HORIZONS-AMI Trial Investigators. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet. 2009; 374: 1149-1159.
7. Pinto DS, Stone GW, Shi C, et al. ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) Investigators. Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes. J Am Coll Cardiol. 2008; 52: 1758-1768.
8. Rassen JA, Mittleman MA, Glynn RJ, et al. Safety and effectiveness of bivalirudin in routine care of patients undergooing percutaneous coronary intervention. Eur Heart J. 2010; 31: 561-572.
9. Schneider DJ, Sobel BE,. Lack of early augmentation of platelet reactivity after coronary intervention in patients treated with bivalirudin. J Thromb Thrombolysis. 2009; 28: 6-9.
10. Kimmelstiel C, Zhang P, Kapur NK, et al. Bivalirudin Is a dual inhibitor of thrombin and collagen-dependent platelet activation in patients undergoing percutaneous coronary intervention. Circ Cardiovasc Interv. 2011; 4: 171-179.
11. Gao C, Boylan B, Fang J, et al. Heparin promotes platelet responsiveness by potentiating αIIbβ3-mediated outside-in signaling. Blood. 2011; 117: 4946-4952.
12. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2010; 31: 2501-2555.
13. Wright RS, Anderson JL, Adams CD, et al. 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non-ST- Elevation Myocardial Infarction (Updating the 2007 Guideline). A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2011; 57: 1920-1959.
14. Ndrepepa G, Schuster T, Hadamitzky M, et al. Validation of the bleeding academic research consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention. Circulation. 2012; 125: 1424-1431.
15. Robinson SD, Janssen C, Fretz EB, et al. Non-red blood cell transfusion as a risk factor for mortality following percutaneous coronary intervention. Int J Cardiol. 2012; 157: 169-173.
16. Rao SV, Jollis JG, Harrington RA, et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA. 2004; 292: 1555-1562.
17. Kim P, Dixon S, Eisenbrey AB, et al. Impact of acute blood loss anemia and red blood cell transfusion on mortality after percutaneous coronary intervention. Clin Cardiol. 2007; 30 (10 suppl 2): II35-II43.
18. Nikolsky E, Mehran R, Sadeghi HM, et al. Prognostic impact of blood transfusion after primary angioplasty for acute myocardial infarction: analysis from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trial. JACC Cardiovasc Interv. 2009; 2: 624-632.
19. Stone GW, McLaurin BT, Cox DA, et al. ACUITY Investigators. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355: 2203-2216.
20. Kastrati A, Neumann FJ, Schulz S, et al. ISAR-REACT 4 Investigators. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. N Engl J Med 2011; 365: 1980-1989.
21. Baumbach A, Johnson TW, Oriolo V, et al. Prasugrel and bivalirudin for primary angioplasty: early results on stent thrombosis and bleeding. Int J Cardiol. 2011; 153: 222-224.
22. Bonello L, Pansieri M, Mancini J, et al. High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. J Am Coll Cardiol. 2011; 58: 467-473.
23. Valgimigli M, Tebaldi M, Campo G, et al. FABOLUS PRO Investigators. Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: The FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial. JACC Cardiovasc Interv. 2012; 5: 268-277.